GLAND PHARMA LIMITED Intrinsic Value

GLAND · Healthcare · Current price ₹2,888.1

Full stock page
DocStoX fair value
₹1,472
low confidence
Current price
₹2,888
Upside to fair value
-49.0%
Verdict
Avoid
Quality score
5.1 / 10
Model it yourself — Intrinsic Value Calculator
Opens pre-filled with GLAND PHARMA LIMITED's latest numbers.

Is GLAND PHARMA LIMITED undervalued?

DocStoX estimates the fair value of GLAND PHARMA LIMITED at ₹1,472 per share, versus the current market price of ₹2,888. That puts the stock about -49.0% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.

How this fair value is calculated

This estimate blends 4 independent methods: Residual income (₹608), Relative P/E (₹2,438), Graham floor (₹939), Analyst target (₹2,834). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.

Bear, base and bull scenarios

Our scenarios span ₹608 (bear) to ₹1,472 (base) to ₹2,834 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.

Margin of safety

Value investors demand a margin of safety — a discount to intrinsic value that protects against being wrong. At ₹2,888 versus an intrinsic value of ₹1,472, GLAND PHARMA LIMITED currently offers -49.0% of negative margin (i.e. a premium).

More on GLAND PHARMA LIMITED

Fair ValueDCFValuationFinancial RatiosPeers

DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.